
It’s official: Roche is a Car-T player
Asset prices fall sufficiently to persuade Roche to sign up to Poseida’s allogeneic cell therapies.

A late Christmas present for Allogene
US clinical hold over Allogene’s entire pipeline has just been lifted.

Ash 2021 movers – IGM steals the show, for all the wrong reasons
At a meeting lacking practice-changing studies and featuring many disappointments the downturn in IGM’s fortunes stands out.

Ash 2021 preview – as competition grows Autolus monetises
Several cell therapy presentations will vie for attention at Ash, though today the spotlight falls on Autolus.

Crispr’s reminder about allogeneic Car-T redosing
Crispr follows Allogene with backing for off-the-shelf Car-T therapy – and adds big concerns over lack of durability.

Allogene raises the spectre of a Car-T nightmare
Little is known about yesterday’s clinical hold on Allogene’s entire pipeline, but chromosomal abnormalities hint at a worst-case scenario.

Amgen doubles down on bispecifics, courtesy of Teneobio
Curiously, the $900m acquisition will not include many of Teneobio’s pipeline projects.

Precision’s itinerant Car-T cells go on another journey
The company overhauls senior management as its lead technology continues being passed from pillar to post. What is going on?

Ash 2020 movers – shorts roasting on an open fire
IGM’s snowballing share price belies some other major Ash winners, and will make Christmas unhappy for funds that had shorted the stock.